Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial… FDA label
Ceftobiprole medocaril · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Ceftobiprole | EXPERIMENTAL | Participants randomized to this arm will receive intravenous (IV) ceftobiprole. |
| Standard-of-Care (SOC) | ACTIVE_COMPARATOR | Participants randomized to this arm will receive intravenous (IV) standard-of-care (SOC) antibiotic treatment selected according to local guidelines or site-specific standard practice. |
| Name | Type | Description |
|---|---|---|
| Ceftobiprole medocaril sodium | DRUG | Ceftobiprole dosing is based on age/body weight and renal function and given at 7.5 mg/kg, 10 mg/kg, or 15 mg/kg (equivalent to 10 mg/kg, 13.3 mg/kg, or 20 mg/kg respectively of ceftobiprole medocaril sodium) q8h, q12h or q24h up to a maximum of 500 mg (equivalent to 667 mg of ceftobiprole medocaril sodium), with all doses infused over 2 hours. |
| Standard of Care (SOC) | DRUG | Dosage is per local product label based on the participant's age/body weight, and, if applicable, renal function. |
Key Inclusion Criteria: * Pediatric age from birth to \< 18 years old, with body weight ≥ 3.7 kg at the time of consent. Participants in the birth to \< 2-year-old cohort should have a gestational age ≥ 37 weeks and postnatal age ≥ 3 days * Parent(s) or legal guardian(s) have provided documented in...